Click here: to donate by Credit Card
Or here: to donate by PayPal
Or by mail to: Free Republic, LLC - PO Box 9771 - Fresno, CA 93794
Thank you very much and God bless you.
Posted on 08/26/2026 7:03:03 PM PDT by Miami Rebel
The Food and Drug Administration on Wednesday approved a groundbreaking pancreatic cancer drug that experts predict will transform treatment for the notoriously deadly disease.
The drug, Revolution Medicines’ Rasonque, or daraxonrasib, was approved for patients with advanced pancreatic cancer who have already tried a prior treatment, such as chemotherapy, the agency said.
In a late-stage clinical trial of 500 patients, people who got the drug lived about twice as long — 13.2 months, on average — compared with people who got chemotherapy.
Dr. Rachna Shroff, chief of the division of hematology and oncology at the University of Arizona Cancer Center in Tucson, previously told NBC News that she “started crying tears of joy” when she saw the trial’s preliminary findings in April.
“It’s that big of a game changer for those of us who treat pancreatic cancer,” Shroff said. “It’s unprecedented.”
The drug does have side effects, including a blistering rash, sores in the mouth and throat, and vomiting and diarrhea. (Former Sen. Ben Sasse of Nebraska, who got the drug in a clinical trial, described the rash as “nuclear” on a New York Times podcast in the spring.)
Channing Der, a pharmacologist at the University of North Carolina at Chapel Hill, called Wednesday’s approval a “monumental moment for the treatment of pancreatic cancer.”
“Pancreatic cancer is the third leading cause of cancer death in the U.S. and the deadliest of all cancers,” Der wrote in an email. “This is just the beginning of more advances to come.”
Taken as a daily pill, Rasonque targets a mutation in a gene called KRAS that’s found in nearly all pancreatic cancers as well as many lung, colorectal, ovarian and other cancers. The gene acts like an on/off switch controlling how cells grow in the body. The mutation causes it to get stuck in the “on” position, spurring cells to grow out of control.
Scientists have known for years that if they could target the mutation, they could force the switch from its “on” position. But efforts have failed until Rasonque.
“This is the start of the RAS revolution and it will be a sea change for cancer moving forward,” Shroff said Wednesday.
More than 67,000 people in the U.S. are expected to be diagnosed with pancreatic cancer this year, according to the American Cancer Society.
It’s one of the most difficult cancers to treat: There is no screening for the cancer, and early symptoms are often so vague that the majority of people are diagnosed at later stages of the disease, when it’s much more difficult to treat. The five-year survival rate for pancreatic adenocarcinoma — the most common form — is 8%.
Revolution Medicines said that more than 2,000 patients have already received Rasonque under an expanded access program that the company started in May.
The drugmaker said the out-of-pocket cost for Rasonque — before insurance and other discounts — will be $39,800 for a month’s supply.
|
|
Click here: to donate by Credit Card Or here: to donate by PayPal Or by mail to: Free Republic, LLC - PO Box 9771 - Fresno, CA 93794 Thank you very much and God bless you. |
Like a lot of new drugs, it's initial cost is insanely expensive, but any family with a member who suffers pancreatic cancer will fight to get it.
I own the stock and warrants and expect that the company will get bought in the next few months. Merck tried buying them at the beginning of the year when the market cap was $30 billion. Management was smart to reject the offer insofar as the capitalization is now $45 billion. I think would-be buyers will be knocking on RVMD's door now that its gotten approval. My guess is that Lilly will succeed.
Financial considerations aside, it's good news for humanity. We lost a friend to pancreatic cancer three and a half years ago and it's a bear of a disease. And as the article says, it might be successful in treating other cancers.
Watching this closely. I have PC.
God bless you.
Thank you!
I own the stock and warrants and expect that the company will get bought in the next few months.
I own RVMD too.
Sorry to hear that. I have a friend who has been dealing with it for quite a while. Prayers for healing.
Sorry to hear that!
Oppenheimer has been the leading bull on the stock. Their analyst raised the target from $230 to $260.
“...Prayers for healing.”
Prayers go up that Blessings may come down. In greater measure, pray for Acceptance.
Thank you. It’s been about a year since I was diagnosed.
Still a lot more life to live!
I pray so.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.